Revelation Biosciences (REVBW) Stock Price, News & Analysis

Company Overview

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

Key Stats

• Today's Range: $0.0101 to $0.0130
• 50-Day Range: $0.0097 to $0.0157
• 52-Week Range: $0.00 to $0.04
• Volume: 108,730 shs
• Average Volume: 84,722 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

REVBW Stock Analysis - Frequently Asked Questions

How have REVBW shares performed this year?

Revelation Biosciences' stock was trading at $0.0070 at the beginning of 2025. Since then, REVBW shares have increased by 62.9% and is now trading at $0.0114.
View the best growth stocks for 2025 here.

Who are Revelation Biosciences' major shareholders?

Top institutional shareholders of Revelation Biosciences include Quaker Wealth Management LLC.

How do I buy shares of Revelation Biosciences?

Shares of REVBW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:REVBW
• CIK: 1810560
• Web: www.revbiosciences.com
• Phone: 917 622 5800
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A